NCT01803451 (GLP-1) is a EARLY_PHASE1 clinical trial of exendin-(9-39) in Post-bariatric Surgery, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT01803451?

NCT01803451 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT01803451?

Interventions in NCT01803451: exendin-(9-39), exendin -(9-39).

What condition does NCT01803451 study?

NCT01803451 studies Post-bariatric Surgery.

Is NCT01803451 still recruiting?

NCT01803451 is currently recruiting now. Last updated 8 September 2025.

Last reviewed 2025-09-08 · How we verify

NCT01803451: GLP-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery

Recruiting now EARLY_PHASE1 Last updated 8 September 2025

What this trial tests

EARLY_PHASE1 trial testing exendin-(9-39) in Post-bariatric Surgery in 80 participants. Currently enrolling.

Timeline

1 November 2005

Primary endpoint
1 August 2026

1 August 2027

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	single
Primary purpose	other
Enrollment	80
Start date	1 November 2005
Primary completion	1 August 2026
Estimated completion	1 August 2027
Sites	2 locations across United States

Drugs / interventions tested

exendin-(9-39)
exendin -(9-39)

Conditions studied

Post-bariatric Surgery — all drugs for Post-bariatric Surgery →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

Adults 18 to 65, any sex, with Post-bariatric Surgery. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The investigator measure glucose, islet and GI hormonal levels in response to meal ingestion as a composite measure and the percentage of contribution of GLP-1 contribution to postprandial insulin levels will also be calculated
Time frame: up to 1 year (10 sessions)

Sponsor's own description

The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism. The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims. 1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
Salehi M, Gastaldelli A, D'Alessio DA. · · 2014 · cited 201× · PMID 24315990 · DOI 10.1053/j.gastro.2013.11.044
Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.
Sridharan K, Sivaramakrishnan G. · · 2025 · PMID 41126373 · DOI 10.1186/s13098-025-01988-y

Verify or expand the search:

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01803451 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 8 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01803451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing